These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 30635292)
41. Authors' response to 'TAP deficiency is also a cause of bronchiectasis'. Whitters D; Stockley RA Thorax; 2013 May; 68(5):491. PubMed ID: 23717829 [No Abstract] [Full Text] [Related]
42. Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis. Mayer-Hamblett N; Kloster M; Rosenfeld M; Gibson RL; Retsch-Bogart GZ; Emerson J; Thompson V; Ramsey BW Clin Infect Dis; 2015 Sep; 61(5):707-15. PubMed ID: 25972024 [TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of long-term inhaled antibiotic for patients with noncystic fibrosis bronchiectasis: a meta-analysis. Yang JW; Fan LC; Lu HW; Miao XY; Mao B; Xu JF Clin Respir J; 2016 Nov; 10(6):731-739. PubMed ID: 25620629 [TBL] [Abstract][Full Text] [Related]
44. Chronic colonization by Pseudomonas aeruginosa of patients with obstructive lung diseases: cystic fibrosis, bronchiectasis, and chronic obstructive pulmonary disease. Valderrey AD; Pozuelo MJ; Jiménez PA; Maciá MD; Oliver A; Rotger R Diagn Microbiol Infect Dis; 2010 Sep; 68(1):20-7. PubMed ID: 20727465 [TBL] [Abstract][Full Text] [Related]
45. Pseudomonas eradication in cystic fibrosis: who will join the ELITE? Smyth AR Thorax; 2010 Apr; 65(4):281-2. PubMed ID: 20388748 [No Abstract] [Full Text] [Related]
46. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Davies G; Wells AU; Doffman S; Watanabe S; Wilson R Eur Respir J; 2006 Nov; 28(5):974-9. PubMed ID: 16899482 [TBL] [Abstract][Full Text] [Related]
47. Role of chronic Pseudomonas aeruginosa infection in the development of bronchiectasis. Nagaki M; Shimura S; Tanno Y; Ishibashi T; Sasaki H; Takishima T Chest; 1992 Nov; 102(5):1464-9. PubMed ID: 1424868 [TBL] [Abstract][Full Text] [Related]
49. The existence of bronchiectasis predicts worse prognosis in patients with COPD. Mao B; Lu HW; Li MH; Fan LC; Yang JW; Miao XY; Xu JF Sci Rep; 2015 Jun; 5():10961. PubMed ID: 26077673 [TBL] [Abstract][Full Text] [Related]
50. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200 [TBL] [Abstract][Full Text] [Related]
51. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Drobnic ME; Suñé P; Montoro JB; Ferrer A; Orriols R Ann Pharmacother; 2005 Jan; 39(1):39-44. PubMed ID: 15562142 [TBL] [Abstract][Full Text] [Related]
52. The Multiple Faces of Non-Cystic Fibrosis Bronchiectasis. A Cluster Analysis Approach. Martínez-García MÁ; Vendrell M; Girón R; Máiz-Carro L; de la Rosa Carrillo D; de Gracia J; Olveira C Ann Am Thorac Soc; 2016 Sep; 13(9):1468-75. PubMed ID: 27348199 [TBL] [Abstract][Full Text] [Related]
53. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis. Gillham MI; Sundaram S; Laughton CR; Haworth CS; Bilton D; Foweraker JE J Antimicrob Chemother; 2009 Apr; 63(4):728-32. PubMed ID: 19193658 [TBL] [Abstract][Full Text] [Related]
54. Wang H; Ji XB; Mao B; Li CW; Lu HW; Xu JF BMJ Open; 2018 Mar; 8(3):e014613. PubMed ID: 29540404 [TBL] [Abstract][Full Text] [Related]